JP2021519786A - チエノピリミジノン化合物 - Google Patents
チエノピリミジノン化合物 Download PDFInfo
- Publication number
- JP2021519786A JP2021519786A JP2020552869A JP2020552869A JP2021519786A JP 2021519786 A JP2021519786 A JP 2021519786A JP 2020552869 A JP2020552869 A JP 2020552869A JP 2020552869 A JP2020552869 A JP 2020552869A JP 2021519786 A JP2021519786 A JP 2021519786A
- Authority
- JP
- Japan
- Prior art keywords
- unsubstituted
- substituted
- alkyl
- compound
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 0 C*(C(C1)*1C(*)(C(N1*)=O)N(C(*)=Nc2c3c(*)c(C)[s]2)C3=*)(C1=O)S Chemical compound C*(C(C1)*1C(*)(C(N1*)=O)N(C(*)=Nc2c3c(*)c(C)[s]2)C3=*)(C1=O)S 0.000 description 8
- AVMFYYSOWAUJPF-UHFFFAOYSA-N CC(N1C(CCC(N2)=O)C2=O)=Nc2c(CN)[s]cc2C1=O Chemical compound CC(N1C(CCC(N2)=O)C2=O)=Nc2c(CN)[s]cc2C1=O AVMFYYSOWAUJPF-UHFFFAOYSA-N 0.000 description 3
- VOADSBSPJRDUFY-UHFFFAOYSA-N CC(N(C(CC(N1)=O)C1=O)C1=O)=Nc2c1[s]cc2 Chemical compound CC(N(C(CC(N1)=O)C1=O)C1=O)=Nc2c1[s]cc2 VOADSBSPJRDUFY-UHFFFAOYSA-N 0.000 description 2
- SMZIBQWTMZXISR-UHFFFAOYSA-N CC(N(C(CCC(N1)=O)C1=O)C1=O)=Nc2c1[s]cc2N Chemical compound CC(N(C(CCC(N1)=O)C1=O)C1=O)=Nc2c1[s]cc2N SMZIBQWTMZXISR-UHFFFAOYSA-N 0.000 description 2
- KMRCYDIBIUWZAG-UHFFFAOYSA-N CC(N(C(CCCC(N1)=O)C1=O)C1=O)=Nc2c1[s]cc2 Chemical compound CC(N(C(CCCC(N1)=O)C1=O)C1=O)=Nc2c1[s]cc2 KMRCYDIBIUWZAG-UHFFFAOYSA-N 0.000 description 2
- RQFGQGFRYHUPER-UHFFFAOYSA-N CC(N1C(CCC(N2)=O)C2=O)=Nc([s]c(Br)c2)c2C1=O Chemical compound CC(N1C(CCC(N2)=O)C2=O)=Nc([s]c(Br)c2)c2C1=O RQFGQGFRYHUPER-UHFFFAOYSA-N 0.000 description 2
- OEEHPOMVWAXTRT-UHFFFAOYSA-N CC(N1C(CCC(N2)=O)C2=O)=Nc([s]cc2N)c2C1=O Chemical compound CC(N1C(CCC(N2)=O)C2=O)=Nc([s]cc2N)c2C1=O OEEHPOMVWAXTRT-UHFFFAOYSA-N 0.000 description 2
- ZMEZEXYARKNAHZ-UHFFFAOYSA-N Cc([s]c(N=C(C)N1C(CCC(N2)=O)C2=O)c2C1=O)c2N Chemical compound Cc([s]c(N=C(C)N1C(CCC(N2)=O)C2=O)c2C1=O)c2N ZMEZEXYARKNAHZ-UHFFFAOYSA-N 0.000 description 2
- WQOKERKHMDXXRB-UHFFFAOYSA-N CC(N(C(CCC(N1)=O)C1=O)C1=O)=Nc2c1[s]c(Br)c2 Chemical compound CC(N(C(CCC(N1)=O)C1=O)C1=O)=Nc2c1[s]c(Br)c2 WQOKERKHMDXXRB-UHFFFAOYSA-N 0.000 description 1
- SXOCMQYDNWBCLR-UHFFFAOYSA-N CC(N(C(CCC(N1)=O)C1=O)C1=O)=Nc2c1[s]cc2 Chemical compound CC(N(C(CCC(N1)=O)C1=O)C1=O)=Nc2c1[s]cc2 SXOCMQYDNWBCLR-UHFFFAOYSA-N 0.000 description 1
- NRBWTRGTKRBBJA-UHFFFAOYSA-N CC(N1C(CCC(N2)=O)C2=O)=Nc([s]cc2)c2C1=O Chemical compound CC(N1C(CCC(N2)=O)C2=O)=Nc([s]cc2)c2C1=O NRBWTRGTKRBBJA-UHFFFAOYSA-N 0.000 description 1
- ABQRNRGXTJBMBC-UHFFFAOYSA-N CC(N1C(CCC(N2)=O)C2=O)=Nc([s]cc2Br)c2C1=O Chemical compound CC(N1C(CCC(N2)=O)C2=O)=Nc([s]cc2Br)c2C1=O ABQRNRGXTJBMBC-UHFFFAOYSA-N 0.000 description 1
- KQDWJPMIYYVQKI-UHFFFAOYSA-N CC(N1C(CCC(N2)=O)C2=O)=Nc2c[s]cc2C1=O Chemical compound CC(N1C(CCC(N2)=O)C2=O)=Nc2c[s]cc2C1=O KQDWJPMIYYVQKI-UHFFFAOYSA-N 0.000 description 1
- KSTFGZAZOOBGBZ-UHFFFAOYSA-N Cc1cc(C(N(C(CCC(N2)=O)C2=O)C(C)=N2)=O)c2[s]1 Chemical compound Cc1cc(C(N(C(CCC(N2)=O)C2=O)C(C)=N2)=O)c2[s]1 KSTFGZAZOOBGBZ-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650922P | 2018-03-30 | 2018-03-30 | |
| US62/650,922 | 2018-03-30 | ||
| PCT/US2019/024612 WO2019191451A1 (en) | 2018-03-30 | 2019-03-28 | Thienopyrimidinone compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021519786A true JP2021519786A (ja) | 2021-08-12 |
| JPWO2019191451A5 JPWO2019191451A5 (https=) | 2022-04-04 |
| JP2021519786A5 JP2021519786A5 (https=) | 2022-04-04 |
Family
ID=66102328
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020552869A Pending JP2021519786A (ja) | 2018-03-30 | 2019-03-28 | チエノピリミジノン化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10584133B2 (https=) |
| EP (1) | EP3774815A1 (https=) |
| JP (1) | JP2021519786A (https=) |
| CN (1) | CN112313236A (https=) |
| AU (1) | AU2019243186A1 (https=) |
| CA (1) | CA3094988A1 (https=) |
| TW (1) | TW202003524A (https=) |
| WO (1) | WO2019191451A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021105335A1 (en) * | 2019-11-27 | 2021-06-03 | Captor Therapeutics S.A. | Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof |
| WO2021207530A1 (en) * | 2020-04-08 | 2021-10-14 | Remix Therapeutics Inc. | Compounds and methods for modulating splicing |
| WO2022061348A1 (en) | 2020-09-16 | 2022-03-24 | Biotheryx, Inc. | Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| WO2022087335A1 (en) | 2020-10-23 | 2022-04-28 | Biotheryx, Inc. | Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications |
| TW202237580A (zh) | 2020-12-14 | 2022-10-01 | 美商拜歐斯瑞克斯公司 | Pde4降解劑、醫藥組合物及治療應用 |
| JP2024504932A (ja) | 2021-01-13 | 2024-02-02 | モンテ ローザ セラピューティクス， インコーポレイテッド | イソインドリノン化合物 |
| WO2022255890A1 (en) * | 2021-06-01 | 2022-12-08 | Captor Therapeutics S.A. | Compounds which bind to cereblon, and use thereof |
| WO2023001028A1 (zh) * | 2021-07-19 | 2023-01-26 | 南京明德新药研发有限公司 | 杂芳-3-哌啶二酮类化合物及其应用 |
| WO2023069731A1 (en) * | 2021-10-22 | 2023-04-27 | Monte Rosa Therapeutics, Inc. | Compounds that mediate protein degradation and methods of use thereof |
| US12419962B2 (en) | 2022-03-16 | 2025-09-23 | Biotheryx, Inc. | Quinazolines, pharmaceutical compositions, and therapeutic applications |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016516821A (ja) * | 2013-04-17 | 2016-06-09 | シグナル ファーマシューティカルズ，エルエルシー | 癌を治療するためのｔｏｒキナーゼ阻害剤及び５−置換キナゾリノン化合物を含む組合せ療法 |
| WO2017161119A1 (en) * | 2016-03-16 | 2017-09-21 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Small molecules against cereblon to enhance effector t cell function |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5334596A (en) | 1993-05-11 | 1994-08-02 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
| FR2750862B1 (fr) | 1996-07-12 | 1998-10-16 | Dupin Jean Pierre | Utilisation d'heterocycles diazotes fusionnes avec un systeme aromatique ou heteroaromatique pour le traitement des maladies thrombo-emboliques |
| US6281230B1 (en) * | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
| DE60326436D1 (en) | 2002-03-13 | 2009-04-16 | Janssen Pharmaceutica Nv | Aminoderivate als histone-deacetylase-inhibitoren |
| KR101153335B1 (ko) | 2003-09-24 | 2012-07-05 | 메틸진 인코포레이티드 | 히스톤 데아세틸라제의 억제제 |
| WO2005047293A1 (en) | 2003-11-07 | 2005-05-26 | Neurocrine Biosciences, Inc. | Melanin-concentrating hormone receptor antagonists and compositions and methods related thereto |
| CN1939922B (zh) * | 2005-09-27 | 2010-10-13 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的5H-噻吩[3，4-c]吡咯-4，6-二酮衍生物 |
| EP2616442B8 (en) | 2010-09-14 | 2018-10-17 | Exelixis, Inc. | Inhibitors of pi3k-delta and methods of their use and manufacture |
| AU2012229300B2 (en) * | 2011-03-11 | 2017-04-20 | Celgene Corporation | Methods of treating cancer using 3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-piperidine-2,6-dione |
| US20130116241A1 (en) | 2011-11-09 | 2013-05-09 | Abbvie Inc. | Novel inhibitor compounds of phosphodiesterase type 10a |
| KR101446680B1 (ko) | 2013-02-08 | 2014-10-07 | 한국과학기술연구원 | ｍＧｌｕＲ1 길항제로 작용하는 사이에노피리미디논 유도체 |
| AR106472A1 (es) | 2015-10-26 | 2018-01-17 | Gilead Apollo Llc | Inhibidores de acc y usos de los mismos |
| RU2018117503A (ru) | 2015-10-27 | 2019-11-28 | Мерк Шарп И Доум Корп. | ЗАМЕЩЕННЫЕ ИНДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RORγТ И ИХ ПРИМЕНЕНИЕ |
| CA3010801A1 (en) * | 2016-01-08 | 2017-07-13 | Celgene Corporation | Methods for treating cancer and the use of biomarkers as a predictor of clinical sensitivity to therapies |
| CA3043938A1 (en) * | 2016-12-21 | 2018-06-28 | Biotheryx, Inc. | Thienopyrrole derivatives for use in targeting proteins, compositions, methods, and uses thereof |
| US10406165B2 (en) * | 2017-03-14 | 2019-09-10 | Biotheryx, Inc. | Compounds targeting proteins, compositions, methods, and uses thereof |
-
2019
- 2019-03-28 EP EP19716755.4A patent/EP3774815A1/en not_active Withdrawn
- 2019-03-28 WO PCT/US2019/024612 patent/WO2019191451A1/en not_active Ceased
- 2019-03-28 CA CA3094988A patent/CA3094988A1/en not_active Abandoned
- 2019-03-28 AU AU2019243186A patent/AU2019243186A1/en not_active Abandoned
- 2019-03-28 US US16/368,409 patent/US10584133B2/en active Active
- 2019-03-28 JP JP2020552869A patent/JP2021519786A/ja active Pending
- 2019-03-28 CN CN201980036091.5A patent/CN112313236A/zh active Pending
- 2019-03-29 TW TW108111421A patent/TW202003524A/zh unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016516821A (ja) * | 2013-04-17 | 2016-06-09 | シグナル ファーマシューティカルズ，エルエルシー | 癌を治療するためのｔｏｒキナーゼ阻害剤及び５−置換キナゾリノン化合物を含む組合せ療法 |
| WO2017161119A1 (en) * | 2016-03-16 | 2017-09-21 | H. Lee Moffitt Cancer Center & Research Institute, Inc. | Small molecules against cereblon to enhance effector t cell function |
Non-Patent Citations (1)
| Title |
|---|
| NATURE, vol. 535, JPN6023008352, 2016, pages 252 - 257, ISSN: 0005003423 * |
Also Published As
| Publication number | Publication date |
|---|---|
| TW202003524A (zh) | 2020-01-16 |
| AU2019243186A1 (en) | 2020-10-15 |
| US20190322682A1 (en) | 2019-10-24 |
| US10584133B2 (en) | 2020-03-10 |
| WO2019191451A1 (en) | 2019-10-03 |
| EP3774815A1 (en) | 2021-02-17 |
| CA3094988A1 (en) | 2019-10-03 |
| CN112313236A (zh) | 2021-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021519786A (ja) | チエノピリミジノン化合物 | |
| US11345714B2 (en) | Compounds targeting proteins, compositions, methods, and uses thereof | |
| US11400084B2 (en) | Aminoamide compounds | |
| US10562917B2 (en) | Chimeric compounds targeting proteins, compositions, methods, and uses thereof | |
| US11285218B2 (en) | Degradation of bromodomain-containing protein 9 (BRD9) by conjugation of BRD9 inhibitors with E3 ligase ligand and methods of use | |
| JP6629885B2 (ja) | タンパク質を標的とする化合物、その組成物、方法、および使用 | |
| JP2022510313A (ja) | Ｈｅｌｉｏｓの低分子分解誘導剤および使用方法 | |
| CN113498342A (zh) | 参与协同结合的化合物和其用途 | |
| JP2021527098A (ja) | 縮合チオフェン化合物 | |
| JP2022507267A (ja) | 置換イソインドリノン | |
| TW202019936A (zh) | 雙功能化合物 | |
| CN105073750A (zh) | 布鲁顿氏酪氨酸激酶抑制剂 | |
| US10723705B2 (en) | Heterocyclic compounds and uses thereof | |
| JP2022522890A (ja) | 芳香族誘導体、その調製方法および医薬用途 | |
| US10550125B2 (en) | Prodrugs of imidazotriazine compounds as CK2 inhibitors | |
| US20250092043A1 (en) | Kinase Inhibitors and Degraders | |
| HK40005135A (en) | Pyrazole derivatives, compositions and therapeutic use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220325 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220325 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20230113 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230302 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20231002 |